By ipomarket.in Editorial Team · Last reviewed: 2026-11-20
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Integris Medtech Limited, a medical technology company backed by private equity firm Everstone Capital, has resized its planned initial public offering (IPO). In October 2026 the company revised its fresh issue down to ₹600 crore from an initial plan of ₹925 crore. The move follows SEBI's approval of the offer earlier in the year and signals a more measured approach to the fundraise.
This article walks through what has changed, why it matters, and what retail investors still do not know ahead of the issue.
What Integris Medtech does
Integris Medtech manufactures cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. The company operates across multiple international markets, giving it exposure to both the medical device and diagnostics segments of healthcare.
It is backed by Everstone Capital, a private equity investor, which is a common structure for Indian companies preparing for a public listing. Private equity backing often means a portion of the IPO is structured as an offer for sale (OFS), where existing shareholders sell part of their stake rather than the company raising fresh capital.
The key change: a smaller fresh issue
Integris Medtech initially planned a fresh issue of ₹925 crore. In October 2026, the company revised this down to ₹600 crore. That reduction of ₹325 crore represents a 35.1% decrease from the original plan.
Alongside the smaller fresh issue, the company halved its offer for sale. The OFS was reduced from 2.16 crore shares to 1.08 crore shares in the revised structure. Co-founders Gurmit Singh Chugh and Punita Sharma withdrew their proposed share sales entirely in the revised plan, according to filings reported by Venture Intelligence.
These changes together mean a materially smaller offering than first envisaged, with insiders choosing to retain more of their holdings.
Where the money is going
Approximately 85% of the revised IPO proceeds will be used for debt repayment across the company's subsidiaries. This points to a balance-sheet-focused use of capital rather than expansion or acquisitions.
The scale of the debt helps explain the priority. As of August 31, 2026, Integris Medtech had consolidated borrowings of ₹862.76 crore. Using the bulk of fresh proceeds to pare down this debt would reduce interest costs and strengthen the balance sheet, though it also means less of the capital raised is directed towards growth.
For retail investors, the split between fresh issue and OFS matters. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders. Our explainer on where IPO money goes covers this distinction in detail.
SEBI approval and the offer's history
SEBI approved Integris Medtech's IPO on February 13, 2026. A SEBI approval (observations on the draft prospectus) clears the company to launch its offer, but it does not fix the price band or the opening date.
The original draft red herring prospectus (DRHP) reportedly indicated a total expected IPO size of approximately ₹3,500 to ₹4,000 crore, subject to the book build and market conditions, according to industry reporting. That figure was a reported estimate rather than a confirmed offer size, and the subsequent revisions to both the fresh issue and OFS suggest the final offering will differ from early expectations. Readers should treat the ₹3,500–₹4,000 crore range as an unconfirmed early indication.
If you want to understand how a draft prospectus works and what to look for, see our guide on what a DRHP is and how to read it.
IPO details still pending
Several important details have not been announced yet.
The IPO price band and subscription dates have not been disclosed as of the latest available information. Grey market premium (GMP) data is also not available, since the IPO has not yet opened for subscription. Any GMP figure circulating before the issue opens should be treated with caution. Our guide on how GMP works explains why early grey market signals can be unreliable.
The following parties have been named:
- Book Running Lead Managers (BRLMs): ICICI Securities Ltd., Axis Capital Ltd., Citigroup Global Markets India Private Ltd., and IIFL Capital Services.
- Registrar: KFin Technologies Ltd.
The registrar handles allotment and refunds once the issue closes.
What to watch next
The next milestones will be the announcement of the price band, the subscription window, and the lot size. These figures, together with the company's financials in the updated offer document, will determine how the issue is valued relative to listed medical device and diagnostics peers.
Until the price band is public, it is not possible to assess valuation. Retail investors should wait for the red herring prospectus (RHP) with final figures before drawing conclusions.
FAQ
What is the Integris Medtech IPO date?
The subscription dates have not yet been disclosed. SEBI approved the IPO on February 13, 2026, but the opening and closing dates are still to be announced.
How big is the Integris Medtech IPO?
The fresh issue was revised to ₹600 crore in October 2026, down from an initial ₹925 crore plan, a reduction of 35.1%. The offer for sale was halved to 1.08 crore shares. The total final size will depend on the price band, which has not been announced.
What will the IPO proceeds be used for?
Approximately 85% of the revised proceeds will go towards debt repayment across subsidiaries. As of August 31, 2026, the company had consolidated borrowings of ₹862.76 crore.
Is there a GMP for Integris Medtech IPO?
No. GMP data is not available because the IPO has not yet opened for subscription. Treat any premium figures circulating before the issue opens as unverified.
Who are the lead managers and registrar?
The BRLMs are ICICI Securities, Axis Capital, Citigroup Global Markets India, and IIFL Capital Services. KFin Technologies is the registrar.
Last reviewed: 2026-11-20 by the ipomarket.in Editorial Team.